- ASSISTANT PROFESSOR Genetics and Genomic Sciences
B.Sc. (Hons), Sydney University
Ph.D., University of Queensland
- Dr Greg Holmes received his PhD from The University of Queensland, Australia. In the laboratory of Dr Melissa Little, he characterized protein-DNA and protein-protein interactions of the Wilms’ tumor suppressor gene 1 (WT1) zinc-finger protein and the effect of Denys-Drash syndrome mutations on WT1 DNA binding. His postdoctoral training has been in the laboratories of Lee Niswander (Memorial Sloan-Kettering Cancer Center, NY) studying chick and mouse embryological limb development, and Claudio Basilico (NYU School of Medicine, NY) studying inhibitory interactions of the Fgf signaling pathway on the Wnt signaling pathway, including the role of Sox2, in osteoblasts. While there, he developed a strong interest in craniofacial development, studying a mouse model of the Apert craniosynostosis syndrome. He joined the Jabs lab as an Instructor in 2011 to pursue further research into the molecular processes and tissue interactions underlying a variety of craniosynostosis syndromes.
New topicCraniosynostosis, the premature fusion of cranial sutures, is a relatively common childhood disease (seen in up to 1 in 2500 births), and can occur in isolation or as part of a syndrome affecting other organs in the afflicted individual. Where causative genetic mutations have been identified, mouse models are necessary to study suture fusion and, in the case of syndromic craniosynostosis, the perturbed development of other tissues. We are using a variety of mouse models, particularly of fibroblast growth factor receptor (Fgfr) mutations responsible for Apert, Crouzon, and Beare-Stevenson syndromes, to investigate the changes in molecular pathways and in tissue interactions underlying these syndromes, with a focus on cranial sutures, the palate, and the brain.
Holmes G, Basilico C. Mesodermal expression of Fgfr2(S252W) is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome. Devl Biol 2012; 368(2): 283-293.
Wang Y, Zhou X, Oberoi K, Phelps R, Couwenhoven R, Sun M, Rezza A, Holmes G, Percival CJ, Friedenthal J, Krejci P, Richtsmeier JT, Huso DL, Rendl M, Jabs EW. p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice. J Clin Invest 2012; 122(6): 2153-2164.
Deckelbaum RA, Holmes G, Zhao Z, Tong C, Basilico C, Loomis CA. Regulation of cranial morphogenesis and cell fate at the neural crest-mesoderm boundary by engrailed 1. Development 2012; 139(7): 1346-58.
Holmes G, Bromage TG, Basilico C. The Sox2 high mobility group transcription factor inhibits mature osteoblast function in transgenic mice. Bone 2011; 49(4): 653-61.
Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C. Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 2009; 328(2): 273-84.
Ambrosetti D, Holmes G, Mansukhani A, Basilico C. Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts. Mol Cell Biol 2008; 28(15): 4759-71.
Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 2005; 168(7): 1065-76.
Holmes G, Crooijmans R, Groenen M, Niswander L. ALC (adjacent to LMX1 in chick) is a novel dorsal limb mesenchyme marker. GEP 2003; 3(6): 735-41.
Holmes G, Niswander L. Expression of slit-2 and slit-3 during chick development. Dev Dyn 2001; 222(2): 301-7.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Holmes during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- BioMarin Pharmaceutical Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.